Composition including melittin for removing M2-type tumor-associated macrophage
The present invention relates to a composition including melittin as an active ingredient for removing an M2-type tumor-associated macrophage (TAM), and more specifically, the present invention relates to a composition exhibiting an effect of selectively suppressing only M2-type tumor-associated macrophages among tumor-associated macrophages. The composition according to the present invention only suppresses M2-type tumor-associated macrophages without affecting M1-type tumor-associated macrophages or cancer cells, thus exhibiting anti-cancer and metastasis suppressing effects by blocking angiogenesis through control of the microenvironment of cancer cells, while reducing the side-effects of existing anti-cancer effects.
1. A method for removing tumor-associated macrophage, or treating a tumor-associated macrophage-mediated disease, comprising administering a composition comprising melittin as an active ingredient to a subject in need thereof, wherein the subject requires treatment of suppressing the M2-type tumor-associated macrophage without affecting the M1-type tumor-associated macrophage, wherein the composition increases a ratio (M1/M2) of a M1-type tumor-associated macrophage to a M2-type tumor-associated macrophage as compared to a comparative case where the composition is not administered, wherein the composition suppresses expression of a gene and protein of CD31, and wherein the subject requires a treatment of suppressing a tumor growth without affecting a cell cycle of tumor cells.
2. The method according to claim 1 , wherein a concentration of the melittin administered is 0.1 μg/ml to 2 μg/ml.
3. The method according to claim 1 , wherein the tumor-associated macrophage is the M2-type tumor-associated macrophage.
4. The method according to claim 1 , wherein the tumor-associated macrophage-mediated disease is Lewis lung cancer.